Soft-tissue tumors in young patients

Author(s):  
Cheryl M. Coffin ◽  
Mariana M. Cajaiba ◽  
Justin M. M. Cates ◽  
Rita Alaggio
Author(s):  
Flávia Sprenger ◽  
Sofia Tokars Kluppel ◽  
Valmir Vicente Filho ◽  
Ana Carolina Staats ◽  
Raul Alberto Anselmi Junior ◽  
...  

Abstract Background The term fibromatosis refers to a spectrum of soft tissue tumors resulting from the unbridled proliferation of fibroblasts, with high infiltrative power. It is a rare neoplasm, with an incidence of about 3 cases per million. Most common sites include the abdominal wall and cavity, chest wall, scapular area, and the limbs, rarely affecting the axilla. Imaging plays a major role in surgical planning and clinical follow-up. Differential diagnosis with other soft tissue tumors may be arduous, but a correct evaluation is fundamental. Case presentation A 33-year-old case is reported for the evaluation of a palpable hardened and immobile left axillary nodule. The ultrasound reveals a solid, elongated, heterogeneous, poorly delimited, infiltrative lesion observed in the left axillary hollow, with no detectable flow in the color Doppler mode. At magnetic resonance imaging, the same elongated and expansive lesion was better defined, revealing its irregular contours, alternating areas of hypo- and hyperintense on T2, heterogeneous enhancement, and no signs of signal decay on in- and out-of-phase sequences. Due to its growth and local invasion potential, surgical excision was performed. The microscopic analysis showed long and uniform spindle cell fascicles, with clear cytoplasm and wavy nuclei, arranged in different directions, included in collagen stroma. Immunohistochemistry was positive for nuclear beta-catenin, confirming the diagnosis of fibromatosis. Conclusion Imaging methods reflect the heterogeneous nature of the lesion. This study demonstrates the importance of using a multidisciplinary approach in addition to imaging tests and histopathological study for better diagnosis and therapeutic planning. The high infiltrative power always must be reminded of, since it affects young patients and diagnosis delay can lead to mutilating surgeries.


2002 ◽  
Vol 5 (6) ◽  
pp. 579-586 ◽  
Author(s):  
Neil James Sebire ◽  
Alan Drummond Ramsay ◽  
Gillian Levitt ◽  
Marian Malone ◽  
Rupert Anthony Risdon

Malignant soft tissue tumors other than rhabdomyosarcoma (RMS) are uncommon in infancy, representing approximately 5% of pediatric sarcomas. The pathological categorization of non-RMS soft tissue malignancies from these young patients is complicated by variation in both morphologic and immunohistochemical features. A search covering an 11-year period identified 19 patients presenting at birth or in infancy with a clinical or referral diagnosis of soft tissue sarcoma. After histologic and immunohistochemical review, nine of these tumors were classified as primitive neuroectodermal tumor (PNET), three as infantile hemangiopericytoma (HPC), two as infantile fibrosarcoma (FS), and five as undifferentiated sarcoma. Those identified as undifferentiated sarcomas showed an atypical spindle and ovoid cell morphology, with cellular pleomorphism and high mitotic rate, but lacking the fascicular growth pattern of classic infantile fibrosarcoma. Immunohistochemical staining in this group showed variable weak positivity for a range of markers (desmin, smooth muscle actin, Myo-D1, PGP, NSE, S100, CO56, cytokeratin, and CD99), and did not fit readily into any distinct diagnostic category. In this series, tumors classified as soft tissue PNETs had a poor prognosis despite aggressive treatment. However, once RMS, PNET, and other rare specific lesions are excluded, the remaining undifferentiated sarcomas, despite their unusual morphology and immunohistochemistry, appear to behave in a similar favorable manner to infantile fibrosarcoma.


Author(s):  
D. C. Swartzendruber ◽  
Norma L. Idoyaga-Vargas

The radionuclide gallium-67 (67Ga) localizes preferentially but not specifically in many human and experimental soft-tissue tumors. Because of this localization, 67Ga is used in clinical trials to detect humar. cancers by external scintiscanning methods. However, the fact that 67Ga does not localize specifically in tumors requires for its eventual clinical usefulness a fuller understanding of the mechanisms that control its deposition in both malignant and normal cells. We have previously reported that 67Ga localizes in lysosomal-like bodies, notably, although not exclusively, in macrophages of the spocytaneous AKR thymoma. Further studies on the uptake of 67Ga by macrophages are needed to determine whether there are factors related to malignancy that might alter the localization of 67Ga in these cells and thus provide clues to discovering the mechanism of 67Ga localization in tumor tissue.


2020 ◽  
Vol 24 (06) ◽  
pp. 667-675
Author(s):  
Violeta Vasilevska Nikodinovska ◽  
Slavcho Ivanoski ◽  
Milan Samardziski ◽  
Vesna Janevska

AbstractBone and soft tissue tumors are a largely heterogeneous group of tumors. Biopsy of musculoskeletal (MSK) tumors is sometimes a challenging procedure. Although the open biopsy is still considered the gold standard for the biopsy of MSK lesions, core needle biopsy can replace it in most cases, with similar accuracy and a low complication rate. The biopsy should be performed in a tertiary sarcoma center where the multidisciplinary team consists of at minimum a tumor surgeon, an MSK pathologist, and an MSK radiologist who can assess all steps of the procedure. Several factors can influence the success of the biopsy including the lesion characteristics, the equipment, and the method used for the procedure. This review highlights some of the important aspects regarding the biopsy of the MSK tumors, with special attention to imaging a guided core needle biopsy and highlighting some of the recent advancements and controversies in the field.


1994 ◽  
Vol 35 (4) ◽  
pp. 367-370 ◽  
Author(s):  
J. Gelineck ◽  
J. Keller ◽  
O. Myhre Jensen ◽  
O. Steen Nielsen ◽  
T. Christensen

Author(s):  
Shinji Tsukamoto ◽  
Andreas F. Mavrogenis ◽  
Yasuhito Tanaka ◽  
Costantino Errani

: Differentiation of malignant from benign soft tissue tumors is challenging with imaging alone, including that by magnetic resonance imaging and computed tomography. However, the accuracy of this differentiation has increased owing to the development of novel imaging technology. Detailed patient history and physical examination remain essential for differentiation between benign and malignant soft tissue tumors. Moreover, measurement only of tumor size based on Response Evaluation Criteria In Solid Tumors criteria is insufficient for the evaluation of response to chemotherapy or radiotherapy. Change in metabolic activity measured by 18F-fluorodeoxyglucose positron emission tomography or dynamic contrast enhanced-derived quantitative endpoints can more accurately evaluate treatment response compared to change in tumor size. Magnetic resonance imaging can accurately evaluate essential factors in surgical planning such as vascular or bone invasion and “tail sign”. Thus, imaging plays a critical role in the diagnosis and treatment of soft tissue tumors.


Sign in / Sign up

Export Citation Format

Share Document